Spyre Therapeutics' CEO Sells 15,000 Shares
This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a new SEC filing.
Cameron Turtle, Chief Executive Officer of Spyre Therapeutics (NASDAQ:SYRE), directly sold 15,000 shares in open-market transactions on Jan. 2, for a total consideration of more than $460,000 according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($30.68); post-Transaction value based on Jan. 2, 2026 market close ($30.58).
Source Fool.com
